Free Patent/Trademark Report to Commissioner - District Court of Delaware - Delaware

Case 1 :08-cv-00162-JJF Document 21 Filed 06/24/2008 Page 1 of 1
Q AO 120 Rev. 3/04
TO Mau Stop 8 REPORT on THE
` Director of the U.S. Patent and Trademark Office FILING OR DETERMINATION OF AN
13.6. BOX 1450 ACTION REGARDING A PATENT on
Alexandria, VA 22313-1450 TRADEMARK
In Compliance with 35 U.S.C. § 290 and/or I5 U.S.C. § 1116 you are hereby advised that a court action has been
filed in the U.S. District Court Delaware on the following X Patents or III Trademarks:
DOCKET NO. DATE FILED U.S. DISTRICT COURT
08cv 162 3/24/2008 DISTRICT OF DELAWARE
PLAINTIFF DEFENDANT
Pfizer Inc., et al. Ranbaxy Laboratories Limited, et al.
PATENT OR DATE OF PATENT
TRADEMARK NO. OR TRADEMARK HOLDER OF PATENT OR TRADEMARK
1 6,087,51 I 7/1 1/2000 Wamer-Lambert Company
2 6,274,740 8/ 14/2001 Wamer-Lambert Company
3 __
3 __
3 __
In the above—entitIed case, the following patent(s)/ trademark(s) have been included:
DATE INCLUDED INCLUDED BY
I] Amendment lj Answer [I Cross Bill III Other Pleading
PATENT OR DATE OF PATENT
TRADEMARK NO. OR TRADEMARK HOL[)ER OF PATENT OR TRADEMARK
3 __
3 __
3
3 __
3
In the ab0ve——entitIed case, the following decision has been rendered orjudgement issued:
DECISION/IUDGEMENT
See Attached Consent Order and Stipulated Injunction
CLERK (BY) DEPUTY CLERK DATE
PETER T. DALLEO, CLERK OF COURT I W A ,.` A V VIZ 6/24/2008
Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon tiling document adding patent(s), mail this copy to Director Copy 4—Case file copy

Case 1 :08-cv-00162-JJF Document 21 -2 Filed 06/24/2008 Page 1 of 3
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
1
Pfizer Inc., )
Pfizer Ireland Pharmaceuticals, )
Warner-Lambert Company, )
Warner-Lambert Company LLC and )
Warner-Lambert Export Limited, )
)
Plaintiffs/Counterclaim-Defendants )
)
v. )
) C.A. No. 08-cv-162-JIF
1
Ranbaxy Laboratories Limited )
Ranbaxy Pharmaceuticals, Inc. and )
Ranbaxy, Inc, )
1
Defendant/Counterclaim-Plaintiff )
CONSENT ORDER AND STIPULATED INJUNCTION
WHEREAS, plaintiffs/counterclaim defendants Pfizer Inc., Pfizer Ireland
Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC and
Warner-Lambert Export Limited ("Pfizer") own U.S. patents covering the manufacture,
sale and use of products containing atowastatin and amlodipine, and any
pharmaceutically acceptable salts thereof, including without limitation U.S. patents
6,087,511 and 6,274,740 (collectively, "Process Patents");
WHEREAS, defendant/counterclaim plaintiff Ranbaxy Laboratories Limited and
Ranbaxy, Inc. ("Ranbaxy") has submitted to the U.S. Food and Drug Administration
Abbreviated New Drug Application No. 78-747 ("Ranbaxy ANDA") for approval to

Case 1:08-cv-00162-JJF Document 21-2 Filed 06/24/2008 Page 2 of 3
market and sell a generic product containing atorvastatin calcium and amlodipine
besylate;
WHEREAS, Pfizer and Ranbaxy are parties to litigation relating to the Ranbaxy
ANDA and Process Patents, and Ranbaxy desirest 0 sell a generic product containing
atorvastatin calcium and amlodipine besylate under the Ranbaxy ANDA iiee from claims
of iniiingement by Pfizer under the Process Patents;
WHEREAS, Pfizer andR anbaxy have entered intoa Settlement andL icense
Agreement, dated as of June 17, 2008 ("Settlement Agreement"), pursuant to which the
parties have resolved this action and Pfizer has granted Ranbaxy certain rights to its
portfolio of patents relating to atorvastatin;
NOW THEREFORE, Pfizer and Ranbaxy stipulate that:
1. Ranbaxy, its officers, agents,s ervants, employees and attorneys, and those
persons in active concert or participation with Ranbaxy are enjoined until November 30,
201 1 fiom engaging in the commercial manufacture, use, offer to sell, or sale within the
UnitedS tates, or importationi ntot he UnitedS tates, of any product comprising the
chemical compounds atorvastatin calcium and amlodipine besylate. This injunction shall
terminate automatically upon the U.S. Generic Lipitor Commencement Date as defined in
the Settlement Agreement.
2. The Protective Order entered by the Court in this action shall remain in
full force and effect notwithstanding this Consent Order and Stipulated injunction.
3. All claims and counterclaims are dismissed with prejudice, and each Party
shall bear its own costs, expenses and attorneys’ fees in connection with this action.
4. The parties waive any right of appeal from this Order.
2

Case 1:08-cv-00162-JJF Document 21-2 Filed 06/24/2008 Page 3 of 3
5. The Court reserves jurisdiction over this Consent Order in the evento f any
dispute concerning it.
Dated: June 18,200 8 Dated: June 18, 2008
By: /s/ Rudolf E. Hutz By: /s/ Frederick L. Cottre//, III
Rudolf E· Hutz (#484) Frederick L.c ottrell, III (#2555)
Jeffrey B- BeVe (#998) Email: [email protected]
MMV W- Bourke (#2356) Richards, Layton & Finger
CONNOLLY BOVE LODGE & HUTZ LLP Ono Rodney Sqnoio
The Nemours Building p_(_)_ Box 55]
1007 North Orange Street Wilmington, DE igggg
PQ- BOX 2207 (302) 658-6541
Wllmmgtem DE 198992207 Attorneys jbr Defendants
(302) 658-9141
Attorneys for the P/aint#* (jfcounsoii
Joseph M. Reisman
William R. Zimmerman
Payson LeMeilleur
KNOBBE, MARTENS, OLSON
& BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
(949) 760-0404
Attorneys for Defendants
IT IS SO ORDERED, this 8`QD day of , 2008.
\ . , `
AlLc..r.4& W
Honor ble eph J. Farnan,
ted States District Judge
3

Case 1:08-cv-00162-JJF

Document 21

Filed 06/24/2008

Page 1 of 1

Case 1:08-cv-00162-JJF

Document 21-2

Filed 06/24/2008

Page 1 of 3

Case 1:08-cv-00162-JJF

Document 21-2

Filed 06/24/2008

Page 2 of 3

Case 1:08-cv-00162-JJF

Document 21-2

Filed 06/24/2008

Page 3 of 3